ustekinumab
Sign in to saveAlso known as Stelera, CNTO-1275, TT-20, Anti-IL12/23
Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication used for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23. It is administered either by intravenous infusion or subcutaneous injection. The antibody targets a subunit of human interleukin 12 and interleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. Ustekinumab was developed by Centocor Ortho Biotech.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470627281
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- IL-12 and IL-23
- Drug.tradename
- Stelara
- Drug.MedlinePlus
- a611013
- Drug.DailyMedID
- Ustekinumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous, intravenous
- Drug.class
- Immunosuppressant interleukin inhibitor
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC05
- Drug.biosimilars
- ustekinumab-aauz, ustekinumab-aekn, ustekinumab-auub, ustekinumab-hmny, ustekinumab-kfce, ustekinumab-srlf, ustekinumab-stba, ustekinumab-ttwe, Absimky, Eksunbi, Fymskina, Imuldosa, Jamteki, Otulfi, Pyzchiva, Qoyvolma, Selarsdi, Starjemza, Steqeyma, Usgena, Usrenty, Uzpruvo, Wezlana, Wezenla, Yesintek
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Research
4,360 papers- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.Lancet (London, England) · 2018
- AVT04: An Ustekinumab Biosimilar.Clinical drug investigation · 2024
- Ustekinumab for treating ulcerative colitis: an expert opinion.Expert opinion on biological therapy · 2020
- Off-label uses of ustekinumab.Dermatologic therapy · 2022
- [Ustekinumab - Current position].Zeitschrift fur Gastroenterologie · 2018
via PubMed
~14 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Adverse effects
- Pregnancy
- Mechanism of action
- History
- Society and culture
- Legal status
- Biosimilars
- References
Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication used for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23. It is administered either by intravenous infusion or subcutaneous injection. The antibody targets a subunit of human interleukin 12 and interleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. Ustekinumab was developed by Centocor Ortho Biotech.
Ustekinumab (an immunosuppressant interleukin inhibitor) is a fully human IgG1κ monoclonal antibody that binds to the shared p40 protein subunit of interleukin (IL) 12 and 23, thereby preventing them from binding to the IL-12Rβ1 receptor protein expressed on the surface of immune cells. By doing so, ustekinumab prevents the activation of the Th1 and Th17 cytokine pathways, which are central to the pathology of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
Excerpted from Wikipedia’s “ustekinumab” article, available under the CC BY-SA 4.0 licence.